WuXi Biologics plans on-market share buyback of up to US$400 million
PUBT · 05/26 00:02
Share
Listen to the news
- WuXi Biologics launched an on-market share repurchase program with an aggregate cap of USD 400 million.
- Board resolution dated May 24, 2026; buybacks to be executed from time to time in the open market.
- Program to use an existing repurchase mandate that allows up to 406,868,077 shares, equal to 10% of shares outstanding at June 6, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12170044), on May 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending